WÃ¤denswil/Zurich, SwitzerlandÂ â€“ Creoptix AG, a Switzerland-based company focused on next-generation bioanalytical instruments, today announcedÂ that is has raised CHF 8 million in the first closing as part of a Series C financing round.Â The round was led by Swisscanto Invest by ZÃ¼rcher Kantonalbank and joined by Waters Corporation (NYSE: WAT) as well as existing private investors. Robert Schier of Swisscanto Invest has joined the board of director.Â With this financing round, the company has raised more than CHF 15 million since 2013.The proceeds enable Creoptix to strengthen its commercial operations in Europe as well as in the US and to expand its market presence.Â
Creoptix developed and markets Creoptix WAVE systems to study molecular interactions in real-time and is revolutionizing the world of drug discovery. Based on proprietary waveguide interferometry technology, the Creoptix WAVE system offers a level of sensitivity superior to Surface Plasmon Resonance (SPR), with a crude sample robustness normally only achieved with plate-based assays. The technology is facilitating new analytical applications such as membrane protein analysis in drug discovery and real-time kinetic interaction studies in body fluids for biomarker and biotherapeutics development.
Robert Schier, Investment Director PE/VC Health-Tech at Swisscanto Invest,Â commented: “Creoptix WAVE systems convinces as a mature, robust, versatile and sensitive technology that addresses many existing and novel applications in life sciences. Swisscanto Invest also sees excellent commercial potential, which has been confirmed by existing customers and increasing revenues this year. Creoptix is a great match for our growth fund and we are proud to be part of an exciting journey.”
“We are delighted to have attracted Swisscanto Invest as an institutional investor and are very pleased with the support we have received from our existing investors, including Waters Corporation. This financing round provides us with the funds to support our plans to grow our commercial operations and to expand our presence in the market,”Â said Matyas Vegh, CEO of Creoptix.
Eduard M. Brunner, Chairman of Creoptix, added:Â “Creoptix, with its next-generation WAVE systems, has significant potential to make a real impact on the bioanalytical instruments market. We are pleased to welcome Swisscanto Invest as a new investor that will help drive our innovation in the years ahead.”
Creoptix is a private company headquartered in WÃ¤denswil, near Zurich, Switzerland, and with US offices in the Boston area. Creoptix focuses on next-generation bioanalytical instruments for drug discovery and development as well as academic research. Based on its proprietary sensor and microfluidics technology, the Creoptix WAVE systems provide exceptionally high sensitivity and resolution in characterizing real-time interactions between small molecules, peptides, proteins and other molecules and even in crude samples like undiluted serum or plasma.Â www.creoptix.com
About Swisscanto Invest by ZÃ¼rcher Kantonalbank
Proven specialists develop high-quality investment and pension solutions for private investors, companies and institutions under the Swisscanto Invest by ZÃ¼rcher Kantonalbank brand. With its Swisscanto Invest by ZÃ¼rcher Kantonalbank brand, the ZÃ¼rcher Kantonalbank group is one of Switzerland’s largest fund providers. It is known for its pioneering role in sustainable investments and its funds regularly achieve national and international recognition.Â www.swisscanto.ch
About Waters Corporation
Waters Corporation (NYSE: WAT), the world’s leading specialty measurement company, has pioneered chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for more than 60 years. With approximately 7,200 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries.Â www.waters.com